XNAS
BLLN
Market cap4.39bUSD
Oct 08, Last price
95.41USD
1D
-0.36%
1Q
-24.74%
IPO
-4.62%
Name
BillionToOne Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Key people
Oguzhan Atay
Chairman of the Board, Chief Executive Officer, Co-Founder · since 2022
David Tsao
Co-Founder, Chief Technology Officer, Board Member · since 2022
John ten Bosch
Senior Vice President - Laboratory Operations · since 2024
Chief Compliance Officer, General Counsel, Secretary · since 2022
Nancy Johnson
Senior Vice President - Sales and Commercial Operations · since 2021
Thomas Bremner
Independent Director · since 2022
Firat Ileri
Independent Director · since 2019
Independent Director · since 2026
Akshay Rai
Independent Director · since 2024
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY |
|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | |
| Income | |||
Revenues | |||
Cost of revenue | |||
Unusual Expense (Income) | |||
NOPBT | |||
NOPBT Margin | |||
Operating Taxes | |||
Tax Rate | |||
NOPAT | |||
Net income | |||
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | |||
BB yield | |||
| Debt | |||
Debt current | |||
Long-term debt | |||
Deferred revenue | |||
Other long-term liabilities | |||
Net debt | |||
| Cash flow | |||
Cash from operating activities | |||
CAPEX | |||
Cash from investing activities | |||
Cash from financing activities | |||
FCF | |||
| Balance | |||
Cash | |||
Long term investments | |||
Excess cash | |||
Stockholders' equity | |||
Invested Capital | |||
ROIC | |||
ROCE | |||
| EV | |||
Common stock shares outstanding | |||
Price | |||
Market cap | |||
EV | |||
EBITDA | |||
EV/EBITDA | |||
Interest | |||
Interest/NOPBT |